# Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06)

> **NCT00242294** · PHASE2,PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 570 (—)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Roflumilast

## Key facts

- **NCT ID:** NCT00242294
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2006-09
- **Final completion:** 2007-03
- **Target enrollment:** 570 (—)
- **Last updated:** 2016-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00242294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00242294, "Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00242294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*